Aspirin may reduce elevated risk of cancer caused by obesity
the ONA take:
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome, according to a new study published online ahead of print in the Journal of Clinical Oncology has shown.
"This is important for people with Lynch Syndrome but affects the rest of us too. Lots of people struggle with their weight and this suggests the extra cancer risk can be cancelled by taking an aspirin," Professor Sir John Blum, professor of Clinical Genetics at Newcastle University in Leeds, UK, said.
For the study, researchers enrolled 937 patients with Lynch syndrome and randomly assigned them to receive aspirin 600 mg per day or placebo, plus resistant starch 30 g per day or placebo. Results showed that during a median follow-up of 55.7 months, the risk of colorectal cancer was nearly 2.5 times higher for overweight participants than for underweight and normal-weight participants.
Obese patients had a 1.77 times increased risk of Lynch syndrome-related cancer compared with normal-weight participants.
The findings suggest that overweight patients with Lynch syndrome are likely to benefit from obesity prevention and/or regular aspirin.
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|